ArticleEndocrine, metabolic & immune disorders drug targets2026
Effects of TGMXD-208, a Novel PI3K Inhibitor, on Adjuvant-induced Arthritis Rats by Suppressing PI3K/AKT Signaling Pathway
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microalgal Active Peptides: Advances in Preparation, Efficacy, and Mechanisms of Hypoglycemic Action.Journal of food science · 2026Review
- Role of the PI3K/AKT signaling pathway in regulating gene expression in rheumatoid arthritis (Review).Molecular medicine reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe PI3K/AKT signaling pathway is critical for immune cell proliferation, differentiation, survival, and inflammatory cytokine release. TGMXD-208, a novel dual PI3K inhibitor, selectively targets both PI3Kδ and PI3Kγ, positioning it as a potential therapeutic agent for Rheumatoid Arthritis (RA).
methodsThis study evaluated ankle joint swelling and arthritis index and employed HE staining, X-ray imaging, and small animal ultrasonography to assess rat joint tissues. Serum antibodies for IL-1β, IL-6, and TNF-α were determined, as well as organ indices for the spleen and thymus. Western blotting and immunohistochemistry were used to measure the expression and phosphorylation of key enzymes in the PI3K/AKT pathway. The study also examined the impact of TGMXD- 208 on hematological parameters and organs.
resultsOur investigation found that TGMXD-208 dramatically reduced ankle redness and swelling, as well as the arthritis index, in rats in the model group. Additionally, TGMXD-208 reduced arthralgia, deformity, and synovial hyperplasia of the knee joint and accelerated blood flow signals, vascular opacities, accumulation of inflammatory cells, and cartilage erosion of the rats' ankle joints to varying degrees. TGMXD-208 therapy markedly reduced serum levels of IL-1β, IL-6, and TNF-α compared to the model group. Besides, it also reduced organ indices. Furthermore, TGMXD-208 diminished the protein levels of p-PI3K and p-AKT. However, hematological parameters were not considerably impacted by TGMXD-208, and no appreciable aberrant alterations were noted in the organs. Discussion: TGMXD-208 alleviates RA pathology by suppressing PI3K/AKT pathway activation and reducing the levels of pro-inflammatory cytokines. Its dual PI3Kδ/γ targeting mitigates synovial hyperplasia and cartilage erosion in AA rats. Notably, 5 mg/kg TGMXD-208 demonstrated safety with no hematological or organ toxicity, supporting its therapeutic potential for RA
conclusionTGMXD-208 cuts down arthritic symptoms in AA rats by blocking the PI3K/AKT pathway, making it a potential treatment option for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.